At the news
? NEUTRALIMPACT 5/10 COURT-RULING filed Apr 12, 2026 at 20:00 ET
The District of New Jersey adopted a Special Master's recommendation to partially dismiss Mylan's antitrust lawsuit against Teva regarding Copaxone. The ruling dismissed claims that Teva's 20mg citizen petitions, 20mg ANDA lawsuit, 2014 FDA lawsuit, 40mg ANDA lawsuit, market-shift strategy, and copay assistance program were anticompetitive, finding they were protected by Noerr-Pennington immunity or failed to plausibly allege causation. However, the court allowed Mylan's claims regarding Teva's DAW (Dispense as Written) campaign, exclusionary agreements with PBMs, and the 2020 reclassification petition to proceed, meaning significant antitrust exposure remains for Teva.
- Court adopted Special Master's 91-page R&R partially granting Teva's motion to dismiss Mylan's antitrust complaint
- DAW campaign allegations, exclusionary PBM agreement allegations, and 2020 reclassification petition claims survive dismissal and will proceed to discovery
- 20mg citizen petitions, 20mg and 40mg ANDA lawsuits, 2014 FDA lawsuit, market-shift allegations, and copay assistance program allegations dismissed with prejudice under Noerr-Pennington immunity
- Non-Orange Book patent litigation allegations excluded from complaint as not pled in original filing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access